Lady  ||| S:0 E:5 ||| NNP
Prelox®  ||| S:5 E:13 ||| NNP
improves  ||| S:13 E:22 ||| VBZ
sexual  ||| S:22 E:29 ||| JJ
function  ||| S:29 E:38 ||| NN
in  ||| S:38 E:41 ||| IN
post-menopausal  ||| S:41 E:57 ||| JJ
women  ||| S:57 E:63 ||| NNS
The  ||| S:63 E:67 ||| DT
aim  ||| S:67 E:71 ||| NN
of  ||| S:71 E:74 ||| IN
this  ||| S:74 E:79 ||| DT
pilot ||| S:79 E:84 ||| NN
,  ||| S:84 E:86 ||| ,
single-blinded  ||| S:86 E:101 ||| JJ
study  ||| S:101 E:107 ||| NN
was  ||| S:107 E:111 ||| VBD
to  ||| S:111 E:114 ||| TO
evaluate  ||| S:114 E:123 ||| VB
the  ||| S:123 E:127 ||| DT
efficacy  ||| S:127 E:136 ||| NN
of  ||| S:136 E:139 ||| IN
a  ||| S:139 E:141 ||| DT
proprietary ||| S:141 E:152 ||| NN
,  ||| S:152 E:154 ||| ,
dietary  ||| S:154 E:162 ||| JJ
supplement  ||| S:162 E:173 ||| NN
Lady  ||| S:173 E:178 ||| NNP
Prelox®  ||| S:178 E:186 ||| NNP
for  ||| S:186 E:190 ||| IN
supporting  ||| S:190 E:201 ||| VBG
and  ||| S:201 E:205 ||| CC
improving  ||| S:205 E:215 ||| VBG
sexual  ||| S:215 E:222 ||| JJ
function  ||| S:222 E:231 ||| NN
in  ||| S:231 E:234 ||| IN
generally  ||| S:234 E:244 ||| RB
healthy ||| S:244 E:251 ||| JJ
,  ||| S:251 E:253 ||| ,
post-menopausal  ||| S:253 E:269 ||| JJ
women ||| S:269 E:274 ||| NNS
.  ||| S:274 E:276 ||| .
The  ||| S:276 E:280 ||| DT
Lady  ||| S:280 E:285 ||| NNP
Prelox®  ||| S:285 E:293 ||| NNP
and  ||| S:293 E:297 ||| CC
placebo  ||| S:297 E:305 ||| JJ
control  ||| S:305 E:313 ||| NN
groups  ||| S:313 E:320 ||| NNS
were  ||| S:320 E:325 ||| VBD
comparable  ||| S:325 E:336 ||| JJ
at  ||| S:336 E:339 ||| IN
inclusion  ||| S:339 E:349 ||| NN
with  ||| S:349 E:354 ||| IN
regard  ||| S:354 E:361 ||| NN
to  ||| S:361 E:364 ||| TO
the  ||| S:364 E:368 ||| DT
total  ||| S:368 E:374 ||| JJ
Female  ||| S:374 E:381 ||| NNP
Sexual  ||| S:381 E:388 ||| NNP
Function  ||| S:388 E:397 ||| NNP
Index  ||| S:397 E:403 ||| NNP
( ||| S:403 E:404 ||| -LRB-
FSFI ||| S:404 E:408 ||| NNP
)  ||| S:408 E:410 ||| -RRB-
score ||| S:410 E:415 ||| NN
,  ||| S:415 E:417 ||| ,
as  ||| S:417 E:420 ||| RB
well  ||| S:420 E:425 ||| RB
as  ||| S:425 E:428 ||| RB
for  ||| S:428 E:432 ||| IN
the  ||| S:432 E:436 ||| DT
six  ||| S:436 E:440 ||| CD
individual  ||| S:440 E:451 ||| JJ
FSFI  ||| S:451 E:456 ||| NNP
domains ||| S:456 E:463 ||| NN
,  ||| S:463 E:465 ||| ,
with  ||| S:465 E:470 ||| IN
40  ||| S:470 E:473 ||| CD
women  ||| S:473 E:479 ||| NNS
( ||| S:479 E:480 ||| -LRB-
50.1  ||| S:480 E:485 ||| CD
±  ||| S:485 E:487 ||| CD
3.1  ||| S:487 E:491 ||| CD
years ||| S:491 E:496 ||| NNS
)  ||| S:496 E:498 ||| -RRB-
and  ||| S:498 E:502 ||| CC
43  ||| S:502 E:505 ||| CD
women  ||| S:505 E:511 ||| NNS
( ||| S:511 E:512 ||| -LRB-
51.2  ||| S:512 E:517 ||| CD
±  ||| S:517 E:519 ||| CD
2.3  ||| S:519 E:523 ||| CD
years ||| S:523 E:528 ||| NNS
) ||| S:528 E:529 ||| -RRB-
,  ||| S:529 E:531 ||| ,
respectively ||| S:531 E:543 ||| RB
.  ||| S:543 E:545 ||| .
At  ||| S:545 E:548 ||| IN
baseline  ||| S:548 E:557 ||| VBG
the  ||| S:557 E:561 ||| DT
women  ||| S:561 E:567 ||| NNS
in  ||| S:567 E:570 ||| IN
the  ||| S:570 E:574 ||| DT
verum  ||| S:574 E:580 ||| JJ
group  ||| S:580 E:586 ||| NN
presented  ||| S:586 E:596 ||| VBN
with  ||| S:596 E:601 ||| IN
a  ||| S:601 E:603 ||| DT
mean  ||| S:603 E:608 ||| JJ
total  ||| S:608 E:614 ||| JJ
FSFI  ||| S:614 E:619 ||| NNP
score  ||| S:619 E:625 ||| NN
of  ||| S:625 E:628 ||| IN
44.6  ||| S:628 E:633 ||| CD
±  ||| S:633 E:635 ||| CD
24.1  ||| S:635 E:640 ||| CD
which  ||| S:640 E:646 ||| WDT
increased  ||| S:646 E:656 ||| VBD
significantly  ||| S:656 E:670 ||| RB
already  ||| S:670 E:678 ||| RB
after  ||| S:678 E:684 ||| IN
four  ||| S:684 E:689 ||| CD
weeks  ||| S:689 E:695 ||| NNS
treatment  ||| S:695 E:705 ||| NN
with  ||| S:705 E:710 ||| IN
Lady  ||| S:710 E:715 ||| NNP
Prelox®  ||| S:715 E:723 ||| NNP
to  ||| S:723 E:726 ||| TO
70.9  ||| S:726 E:731 ||| CD
±  ||| S:731 E:733 ||| CD
18.5  ||| S:733 E:738 ||| CD
and  ||| S:738 E:742 ||| CC
further  ||| S:742 E:750 ||| RB
increased  ||| S:750 E:760 ||| VBN
to  ||| S:760 E:763 ||| TO
71.7  ||| S:763 E:768 ||| CD
±  ||| S:768 E:770 ||| CD
23.9  ||| S:770 E:775 ||| CD
after  ||| S:775 E:781 ||| IN
completion  ||| S:781 E:792 ||| NN
of  ||| S:792 E:795 ||| IN
the  ||| S:795 E:799 ||| DT
eight-week  ||| S:799 E:810 ||| JJ
trial  ||| S:810 E:816 ||| NN
period ||| S:816 E:822 ||| NN
.  ||| S:822 E:824 ||| .
In  ||| S:824 E:827 ||| IN
the  ||| S:827 E:831 ||| DT
control  ||| S:831 E:839 ||| NN
group  ||| S:839 E:845 ||| NN
the  ||| S:845 E:849 ||| DT
mean  ||| S:849 E:854 ||| JJ
total  ||| S:854 E:860 ||| JJ
FSFI  ||| S:860 E:865 ||| NNP
was  ||| S:865 E:869 ||| VBD
44.1  ||| S:869 E:874 ||| CD
±  ||| S:874 E:876 ||| CD
22.8  ||| S:876 E:881 ||| CD
at  ||| S:881 E:884 ||| IN
inclusion  ||| S:884 E:894 ||| NN
and  ||| S:894 E:898 ||| CC
non-significantly  ||| S:898 E:916 ||| NNP
increased  ||| S:916 E:926 ||| VBD
to  ||| S:926 E:929 ||| TO
45  ||| S:929 E:932 ||| CD
±  ||| S:932 E:934 ||| CD
21.4  ||| S:934 E:939 ||| CD
after  ||| S:939 E:945 ||| IN
four  ||| S:945 E:950 ||| CD
weeks  ||| S:950 E:956 ||| NNS
and  ||| S:956 E:960 ||| CC
47.4  ||| S:960 E:965 ||| CD
±  ||| S:965 E:967 ||| CD
21.8  ||| S:967 E:972 ||| CD
after  ||| S:972 E:978 ||| IN
eight  ||| S:978 E:984 ||| CD
weeks ||| S:984 E:989 ||| NNS
,  ||| S:989 E:991 ||| ,
respectively ||| S:991 E:1003 ||| RB
.  ||| S:1003 E:1005 ||| .
The  ||| S:1005 E:1009 ||| DT
treatment  ||| S:1009 E:1019 ||| NN
with  ||| S:1019 E:1024 ||| IN
Lady  ||| S:1024 E:1029 ||| NNP
Prelox®  ||| S:1029 E:1037 ||| NNP
was  ||| S:1037 E:1041 ||| VBD
comparatively  ||| S:1041 E:1055 ||| RB
significantly  ||| S:1055 E:1069 ||| RB
more  ||| S:1069 E:1074 ||| RBR
effective  ||| S:1074 E:1084 ||| JJ
than  ||| S:1084 E:1089 ||| IN
placebo  ||| S:1089 E:1097 ||| NN
after  ||| S:1097 E:1103 ||| IN
both  ||| S:1103 E:1108 ||| DT
four  ||| S:1108 E:1113 ||| CD
and  ||| S:1113 E:1117 ||| CC
eight  ||| S:1117 E:1123 ||| CD
weeks  ||| S:1123 E:1129 ||| NNS
of  ||| S:1129 E:1132 ||| IN
treatment  ||| S:1132 E:1142 ||| NN
( ||| S:1142 E:1143 ||| -LRB-
P  ||| S:1143 E:1144 ||| NNP
< ||| S:1144 E:1145 ||| SYM
0.05 ||| S:1145 E:1149 ||| CD
) ||| S:1149 E:1150 ||| -RRB-
.  ||| S:1150 E:1152 ||| .
The  ||| S:1152 E:1156 ||| DT
individual  ||| S:1156 E:1167 ||| JJ
six  ||| S:1167 E:1171 ||| CD
FSFI  ||| S:1171 E:1176 ||| NNS
domains  ||| S:1176 E:1184 ||| VBP
related  ||| S:1184 E:1192 ||| VBN
to  ||| S:1192 E:1195 ||| TO
desire ||| S:1195 E:1201 ||| NN
,  ||| S:1201 E:1203 ||| ,
arousal ||| S:1203 E:1210 ||| NN
,  ||| S:1210 E:1212 ||| ,
lubrication ||| S:1212 E:1223 ||| NN
,  ||| S:1223 E:1225 ||| ,
orgasm ||| S:1225 E:1231 ||| NN
,  ||| S:1231 E:1233 ||| ,
satisfaction  ||| S:1233 E:1246 ||| NN
and  ||| S:1246 E:1250 ||| CC
pain  ||| S:1250 E:1255 ||| NN
did  ||| S:1255 E:1259 ||| VBD
all  ||| S:1259 E:1263 ||| RB
respond  ||| S:1263 E:1271 ||| VB
favourably  ||| S:1271 E:1282 ||| VBN
to  ||| S:1282 E:1285 ||| TO
treatment  ||| S:1285 E:1295 ||| NN
with  ||| S:1295 E:1300 ||| IN
Lady  ||| S:1300 E:1305 ||| NNP
Prelox® ||| S:1305 E:1312 ||| NNP
;  ||| S:1312 E:1314 ||| :
however ||| S:1314 E:1321 ||| RB
,  ||| S:1321 E:1323 ||| ,
with  ||| S:1323 E:1328 ||| IN
only  ||| S:1328 E:1333 ||| RB
marginable  ||| S:1333 E:1344 ||| VB
higher  ||| S:1344 E:1351 ||| JJR
scores  ||| S:1351 E:1358 ||| NNS
in  ||| S:1358 E:1361 ||| IN
the  ||| S:1361 E:1365 ||| DT
placebo  ||| S:1365 E:1373 ||| JJ
group ||| S:1373 E:1378 ||| NN
.  ||| S:1378 E:1380 ||| .
Four  ||| S:1380 E:1385 ||| CD
women  ||| S:1385 E:1391 ||| NNS
in  ||| S:1391 E:1394 ||| IN
each  ||| S:1394 E:1399 ||| DT
group  ||| S:1399 E:1405 ||| NN
dropped  ||| S:1405 E:1413 ||| VBD
out  ||| S:1413 E:1417 ||| RP
because  ||| S:1417 E:1425 ||| IN
of  ||| S:1425 E:1428 ||| IN
inabilities  ||| S:1428 E:1440 ||| VBG
to  ||| S:1440 E:1443 ||| TO
attend  ||| S:1443 E:1450 ||| VB
scheduled  ||| S:1450 E:1460 ||| VBN
check-ups ||| S:1460 E:1469 ||| JJ
.  ||| S:1469 E:1471 ||| .
No  ||| S:1471 E:1474 ||| DT
adverse  ||| S:1474 E:1482 ||| JJ
effects  ||| S:1482 E:1490 ||| NNS
were  ||| S:1490 E:1495 ||| VBD
reported ||| S:1495 E:1503 ||| VBN
.  ||| S:1503 E:1505 ||| .
This  ||| S:1505 E:1510 ||| DT
study  ||| S:1510 E:1516 ||| NN
opens  ||| S:1516 E:1522 ||| VBZ
an  ||| S:1522 E:1525 ||| DT
interesting  ||| S:1525 E:1537 ||| JJ
perspective  ||| S:1537 E:1549 ||| NN
for  ||| S:1549 E:1553 ||| IN
women  ||| S:1553 E:1559 ||| NNS
experiencing  ||| S:1559 E:1572 ||| VBG
moderate  ||| S:1572 E:1581 ||| JJ
sexual  ||| S:1581 E:1588 ||| JJ
function  ||| S:1588 E:1597 ||| NN
impairment  ||| S:1597 E:1608 ||| NN
and  ||| S:1608 E:1612 ||| CC
suggests  ||| S:1612 E:1621 ||| VBZ
a  ||| S:1621 E:1623 ||| DT
promising  ||| S:1623 E:1633 ||| JJ
new  ||| S:1633 E:1637 ||| JJ
treatment  ||| S:1637 E:1647 ||| NN
option ||| S:1647 E:1653 ||| NN
.  ||| S:1653 E:1655 ||| .
Further  ||| S:1655 E:1663 ||| JJ
studies  ||| S:1663 E:1671 ||| NNS
with  ||| S:1671 E:1676 ||| IN
larger  ||| S:1676 E:1683 ||| JJR
numbers  ||| S:1683 E:1691 ||| NNS
of  ||| S:1691 E:1694 ||| IN
women ||| S:1694 E:1699 ||| NNS
,  ||| S:1699 E:1701 ||| ,
including  ||| S:1701 E:1711 ||| VBG
also  ||| S:1711 E:1716 ||| RB
premenopausal  ||| S:1716 E:1730 ||| JJ
and  ||| S:1730 E:1734 ||| CC
perimenopausal  ||| S:1734 E:1749 ||| JJ
women  ||| S:1749 E:1755 ||| NNS
are  ||| S:1755 E:1759 ||| VBP
warranted ||| S:1759 E:1768 ||| VBN
.  ||| S:1768 E:1770 ||| .
